New Test Launched

• ROS1 gene is a  proto-oncogene which belongs to the subfamily of tyrosine kinase insulin receptor genes.
• ROS protein plays an important role in cell growth and cell specialization.
• Mutations in the ROS1 gene can lead to a type of lung cancer known as non-small cell lung cancer (NSCLC)

Clinical Utility

• ROS1 gene testing is done in patients who are ALK negative
• Prognosis and prediction of response to Crizotinib.
• Monitor progression of the disease in NSCLC patients.

Key Benefits

• ROS1 gene mutation are more common in lung cancer patients who are non smokers and relatively young (average age of 50 years).
• ROS1 mutations have been also linked to cholangiocarcinoma (bile duct cancer) and glioblastoma multiform, a type of brain cancer.

MET GENE TESTING FOR LUNG CANCER

• The MET protein is a receptor kinase that stimulates tyrosine-kinase activity which leads to activation of signalling pathways associated with cell growth and survival.
• MET protein over expression leads to tumor growth and unfavourable prognosis in patients with lung adenocarcinoma.

Clinical Utility

• Met gene testing is done for the prognosis & cause of drug resistance to anti- EGFR TKI
• Monitor progression of the disease in lung carcinoma patients.
• Patients with non-small cell lung cancer and EGFR-activating mutations, which increase sensitivity to tyrosine kinase inhibitor (TKI) therapy, may be resistant to TKI therapy in the presence of MET oncogene amplification

Key Benefits

• MET gene testing by Fish is a confirmatory technique used for the MET gene amplification.
• It identifies a small but clinically important subgroup of gastric cancer patients who are likely to respond to MET-TKIs.